m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0246)

Name	Genotoxicity
ICD	ICD-11: XE2PA

References

Ref 1	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. doi: 10.3816/CBC.2005.n.047.

Cite M6AREG

S. P. Liu, L. Chen, Y. T. Zhang, Y. Zhou, Y. He, Z. Chen, S. S. Qi, J. Y. Zhu, X. D. Chen, H. Zhang, Y. C. Luo, Y. Q. Qiu, L. Tao*, F. Zhu*. M6AREG: m6A-centered regulation of disease development and drug response. Nucleic Acids Research. 2022 Sep 22;gkac801. PMID: 36134713

Correspondence

Prof. Feng ZHU

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

Prof. Shuiping Liu

School of Pharmacy, Hangzhou Normal University, Hangzhou, China

m6A-centered Disease Response Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map